Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
News|Articles|August 30, 2026
FDA Action Update, Week of August 23, 2026: Authorization, Clinical Hold, and Clearance
Author(s)Isabella Ciccone, MPH
Fact checked by: Cheney Gazzam Baltz
Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.
Advertisement
Advertisement
The FDA was busy early this month, during the week of August 23, 2026, making a number of decisions on potential new therapeutic agents, including placing a clinical hold, extending a Prescription Drug User Fee Act (PDUFA) target action date, granting a clearance, a designation and a De Novo marketing authorization.
Related to this article
Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.
Advertisement
Advertisement